

<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.13.8 -->
<!-- Round: afb71e09-2e6f-4dce-be8b-c87d88418aae -->
<!-- Creation date: 2012-03-05T19:08:36Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:acur="http://www.acurapharm.com/20111231" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="acur-20111231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20120229_0" unitRef="shares" decimals="INF">45861120</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat contextRef="eol_PE7738----1110-K0013_STD_0_20110630_0" unitRef="iso4217_USD" decimals="0">45900000</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE7738----1110-K0013_STD_0_20081231_0" unitRef="iso4217_USD" decimals="-3">30398000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20081231_0" unitRef="iso4217_USD" decimals="-3">37064000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-307386000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x444581" unitRef="shares" decimals="-3">42723000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">427000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">344023000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE7738----1110-K0013_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">30174000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">29910000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-323221000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x444581" unitRef="shares" decimals="-3">43728000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">437000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">352694000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1152000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">466000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-335928000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">686000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">45000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">25493000</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">439000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="shares" decimals="-3">43894000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">24441000</us-gaap:AssetsCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">126000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">24045000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PrepaidInsurance contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">213000</us-gaap:PrepaidInsurance>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">25493000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">359830000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">24341000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="shares" decimals="-3">43894000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1052000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="shares" decimals="-3">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">12000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-335928000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="-3">43894000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">439000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">359830000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">530000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:DeferredRevenueCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">-325543000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">477000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">73000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">37173000</us-gaap:Assets>
  <us-gaap:CommonStockValue contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">453000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="shares" decimals="-3">45320000</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:AssetsCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">36129000</us-gaap:AssetsCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ReceivablesNetCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">35685000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PrepaidInsurance contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">218000</us-gaap:PrepaidInsurance>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">37173000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">361733000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">36643000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="shares" decimals="-3">45320000</us-gaap:CommonStockSharesIssued>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">1044000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="shares" decimals="-3">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:IncomeTaxesReceivable contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">153000</us-gaap:IncomeTaxesReceivable>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0" unitRef="iso4217_USD" decimals="-3">53000</us-gaap:AccountsPayableCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-325543000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x444581" unitRef="shares" decimals="-3">45320000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">453000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">361733000</us-gaap:StockholdersEquity>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">9204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromOtherEquity contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ProceedsFromOtherEquity>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">4819000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">147000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">144000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">108000</us-gaap:IncomeTaxesPaid>
  <us-gaap:Revenues contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">3835000</us-gaap:Revenues>
  <us-gaap:CostsAndExpenses contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">17335000</us-gaap:CostsAndExpenses>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">160000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-5203000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">758000</us-gaap:ReimbursementRevenue>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">3000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-13356000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">5039000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">9204000</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.35</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-1113000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">2479000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-15835000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-3172000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">5673000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-683000</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">220000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.35</us-gaap:EarningsPerShareBasic>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">130000</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-13500000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-382000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">11662000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">2479000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-224000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="shares" decimals="-3">45932000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-222000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">-3077000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="shares" decimals="-3">45932000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">160000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">160000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:ProgramFeeRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0" unitRef="iso4217_USD" decimals="-3">3077000</acur:ProgramFeeRevenue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-15835000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueOther>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920_455296x477829" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="shares" decimals="-3">225000</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueOther>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">1000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="shares" decimals="-3">50000</acur:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <acur:AdjustmentsToAdditionalPaidInCapitalShare-BasedCompensationRequisiteServicePeriodRecognitionShares contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581" unitRef="shares" decimals="-3">0</acur:AdjustmentsToAdditionalPaidInCapitalShare-BasedCompensationRequisiteServicePeriodRecognitionShares>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581_455296x477829" unitRef="iso4217_USD" decimals="-3">7000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581_455296x477829" unitRef="shares" decimals="-3">730000</acur:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">9204000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">0</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">-685000</us-gaap:StockIssuedDuringPeriodValueOther>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">159000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698_455296x477829" unitRef="iso4217_USD" decimals="-3">-7000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:SupplementalTaxWithholding contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x441864" unitRef="iso4217_USD" decimals="-3">685000</acur:SupplementalTaxWithholding>
  <acur:CommonStockIssuedShares contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x441864" unitRef="shares" decimals="-3">225000</acur:CommonStockIssuedShares>
  <acur:EquityBasedEmployeeCompensationGrantedShares contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x441864" unitRef="shares" decimals="-3">525000</acur:EquityBasedEmployeeCompensationGrantedShares>
  <acur:CommonStockIssuedShares contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x450439" unitRef="shares" decimals="-3">730000</acur:CommonStockIssuedShares>
  <acur:EquityBasedEmployeeCompensationGrantedShares contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x450439" unitRef="shares" decimals="-3">1479000</acur:EquityBasedEmployeeCompensationGrantedShares>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x477829" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">6746000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromOtherEquity contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ProceedsFromOtherEquity>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-41000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">42000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">28000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">20000</us-gaap:IncomeTaxesPaid>
  <us-gaap:Revenues contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">3311000</us-gaap:Revenues>
  <us-gaap:CostsAndExpenses contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">16035000</us-gaap:CostsAndExpenses>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">392000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-6480000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-14000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">2223000</us-gaap:ReimbursementRevenue>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">14000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-12696000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">6746000</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.27</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">226000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-12707000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-231000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">7177000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">41000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD_per_shares" decimals="2">-0.27</us-gaap:EarningsPerShareBasic>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">135000</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-12724000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">8858000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">11000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-6129000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="shares" decimals="-3">47029000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">37000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestPaid contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">-1088000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="shares" decimals="-3">47029000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">392000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">392000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:ProgramFeeRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0" unitRef="iso4217_USD" decimals="-3">1088000</acur:ProgramFeeRevenue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-12707000</us-gaap:NetIncomeLoss>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x440920_455296x477829" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">0</us-gaap:NetIncomeLoss>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">1000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="-3">123000</acur:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <acur:AdjustmentsToAdditionalPaidInCapitalShare-BasedCompensationRequisiteServicePeriodRecognitionShares contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581" unitRef="shares" decimals="-3">0</acur:AdjustmentsToAdditionalPaidInCapitalShare-BasedCompensationRequisiteServicePeriodRecognitionShares>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581_455296x477829" unitRef="iso4217_USD" decimals="-3">1000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581_455296x477829" unitRef="shares" decimals="-3">43000</acur:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">6746000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">0</us-gaap:NetIncomeLoss>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">391000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x453698_455296x477829" unitRef="iso4217_USD" decimals="-3">-1000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:CommonStockIssuedShares contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_455296x450439" unitRef="shares" decimals="-3">43000</acur:CommonStockIssuedShares>
  <acur:EquityBasedEmployeeCompensationGrantedShares contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_455296x450439" unitRef="shares" decimals="-3">65000</acur:EquityBasedEmployeeCompensationGrantedShares>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20101231_0_455296x477829" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">FY</dei:DocumentFiscalPeriodFocus>
  <dei:EntityVoluntaryFilers contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">No</dei:EntityVoluntaryFilers>
  <dei:TradingSymbol contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">ACUR</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">ACURA PHARMACEUTICALS, INC</dei:EntityRegistrantName>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">Yes</dei:EntityCurrentReportingStatus>
  <dei:AmendmentFlag contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">10-K</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">2011-12-31</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">0000786947</dei:EntityCentralIndexKey>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">141000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">2458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromOtherEquity contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">5000</us-gaap:ProceedsFromOtherEquity>
  <us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE A - DESCRIPTION OF BUSINESS AND SUMMARY OF ACCOUNTING
POLICIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Acura Pharmaceuticals, Inc., a New York corporation, and its
subsidiary (the &amp;#x201C;Company&amp;#x201D;, &amp;#x201C;We&amp;#x201D;, or
&amp;#x201C;Our&amp;#x201D;) is a specialty pharmaceutical company engaged in
research, development and commercialization of products intended to
address medication abuse and misuse, utilizing its proprietary
Aversion&amp;#xAE; and Impede&amp;#x2122; Technologies.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
A summary of the significant accounting policies consistently
applied in the preparation of the accompanying consolidated
financial statements follows.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -11.45pt; MARGIN: 0px 0px 0px 25.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;1. Principles of Consolidation&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The consolidated financial statements include the accounts of the
Company and its wholly-owned subsidiary, Acura Pharmaceutical
Technologies, Inc. All significant intercompany accounts and
transactions are eliminated in consolidation.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;2. Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="COLOR: black"&gt;The Company considers cash and cash
equivalents to include cash in banks, U.S. Treasury Bills, and
institutional money market mutual funds. The Company considers all
highly liquid investments with an original maturity of three months
or less to be cash equivalents.&lt;/font&gt; Our cash and cash
equivalents are governed by our investment policy as approved by
our Board of Directors. The carrying amount of cash and cash
equivalents approximates its fair value due to its short-term
nature.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;3. Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="COLOR: black"&gt;We invest our excess cash in accordance
with the investment policy&lt;/font&gt; approved by our Board of
Directors &lt;font style="COLOR: black"&gt;that seeks both liquidity and
safety of principal. The policy provides for investments in
instruments issued by the United States government and by
commercial institutions with strong investment grade credit ratings
and places restrictions on maturity terms and concentrations by
type and issuer.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: -13.5pt; MARGIN: 0px 0px 0px 13.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;4. Use of Estimates in Consolidated Financial Statements&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The preparation of consolidated financial statements in conformity
with accounting principles generally accepted in the United States
of America requires management to make estimates and use
assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent liabilities at the date of
the consolidated financial statements, as well as the reported
amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates. Management
periodically evaluates estimates used in the preparation of the
consolidated financial statements for continued reasonableness.
Appropriate adjustments, if any, to the estimates used are made
prospectively based on such periodic evaluations.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -11.45pt; MARGIN: 0px 0px 0px 25.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;5. Inventories&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
We had no inventories at each of December 31, 2011 and 2010.
Purchases of active pharmaceutical ingredients and raw materials
required for our development and clinical trial manufacture of
product candidates utilizing our Aversion&amp;#xAE; or Impede&amp;#x2122;
Technologies are expensed as incurred.&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -11.45pt; MARGIN: 0px 0px 0px 25.85pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;6. Property, Plant and Equipment&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Property, plant and equipment are recorded at cost. Depreciation is
recorded on a straight-line basis over the estimated useful lives
of the related assets. Leasehold improvements are amortized on a
straight-line basis over the shorter of their useful lives or the
terms of their respective leases. Betterments are capitalized and
maintenance and repairs are charged to operations as incurred. The
estimated lives of the major classification of depreciable assets
are:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 50%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 60%; TEXT-AUTOSPACE: ideograph-numeric"&gt;Building
and improvements&lt;/td&gt;
&lt;td style="WIDTH: 40%; TEXT-AUTOSPACE: ideograph-numeric"&gt;10 - 40
years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;Land
improvements&lt;/td&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;20 - 40 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;Machinery and
equipment&lt;/td&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;7 - 10 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;Scientific
equipment&lt;/td&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;5 - 10 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;Computer hardware and
software&lt;/td&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;3 - 10 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;Office equipment&lt;/td&gt;
&lt;td style="TEXT-AUTOSPACE: ideograph-numeric"&gt;5 - 10 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0;&lt;/p&gt;
&lt;table style="MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr style="VERTICAL-ALIGN: top"&gt;
&lt;td style="WIDTH: 14.4pt"&gt;&lt;/td&gt;
&lt;td style="WIDTH: 16.6pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
&lt;td&gt;&lt;b&gt;Revenue Recognition, Deferred Program Fee Revenue and
Collaboration Revenue&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 13.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
We recognize revenue when there is persuasive evidence that an
arrangement exists, delivery has occurred, the price is fixed and
determinable, and collection is reasonably assured. In connection
with our License, Development, and Commercialization Agreement
dated October 30, 2007 with King Pharmaceuticals Research and
Development, Inc., now a subsidiary of Pfizer Inc. (the
&amp;#x201C;Pfizer Agreement&amp;#x201D;), we recognize program fee revenue,
collaboration revenue and milestone revenue.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 13.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
Program fee revenue is derived from amortized upfront payments,
such as the $30.0 million upfront payment from Pfizer received in
December 2007, and license fees, such as the $3.0 million option
exercise fee paid by Pfizer to us in each of May 2008 and December
2008 upon the exercise of its option to license a third and fourth
opioid analgesic product candidate under the Pfizer Agreement. We
assigned an equal portion of Pfizer&amp;#x2019;s $30.0 million upfront
payment to each of three product candidates identified in the
Pfizer Agreement and recognize the upfront payment as program fee
revenue ratably over our estimate of the development period for
each identified product candidate.&amp;#xA0; We recognized $0.5
million, $1.1 million, and $3.1 million of this program fee revenue
in 2011, 2010, and 2009, respectively.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 13.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
Collaboration revenue is derived from reimbursement of development
expenses, which are invoiced quarterly in arrears, and are
recognized when costs are incurred pursuant to the Pfizer
Agreement. &amp;#xA0;The ongoing research and development services
being provided to Pfizer under the collaboration are priced at fair
value based upon the reimbursement of expenses incurred pursuant to
the collaboration with Pfizer. We recognized $2.2 million and $0.8
million of collaboration revenue in 2010 and 2009, respectively. We
had no collaboration revenue in 2011.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 13.5pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
Milestone revenue is contingent upon the achievement of certain
pre-defined events in the development of Oxecta Tablets and other
product candidates licensed to Pfizer under the Pfizer Agreement.
&lt;font style="COLOR: black"&gt;Milestone payments from Pfizer are
recognized as revenue upon achievement of the &amp;#x201C;at risk&amp;#x201D;
milestone events, which represent the culmination of the earnings
process related to that milestone. Milestone payments are triggered
either by the results of our research and development efforts or by
events external to us, such as regulatory approval to market a
product. As such, the milestones are substantially at risk at the
inception of the Pfizer Agreement, and the amounts of the payments
assigned thereto are commensurate with the milestone achieved. In
addition, upon the achievement of a milestone event, we have no
future performance obligations related to that milestone payment.
Each milestone payment is non-refundable and non-creditable when
made. In June 2011, Pfizer paid us a $20 million milestone relating
to the receipt of FDA approval of the NDA for Oxecta.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -16.6pt; MARGIN: 0px 0px 0px 31pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;8. Research and Development&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Research and Development&amp;#xA0;(&amp;#x201C;R&amp;amp;D&amp;#x201D;) expenses
include internal R&amp;amp;D activities, external Contract Research
Organization (&amp;#x201C;CRO&amp;#x201D;) services and their clinical
research sites, and other activities. &amp;#xA0;Internal R&amp;amp;D
activity expenses include facility overhead, equipment and facility
maintenance and repairs, laboratory supplies, pre-clinical
laboratory experiments, depreciation, salaries, benefits, and
share-based compensation expenses. CRO activity expenses include
preclinical laboratory experiments and clinical trial studies.
Other activity expenses include regulatory consulting, and
regulatory legal counsel. Internal R&amp;amp;D activities and other
activity expenses are charged to operations as incurred. &amp;#xA0;We
make payments to the CRO&apos;s based on agreed upon terms and may
include payments in advance of a study starting date. We review and
accrue CRO expenses and clinical trial study expenses based on
services performed and rely on estimates of those costs applicable
to the stage of completion of a study as provided by the CRO.
&amp;#xA0;Accrued CRO costs are subject to revisions as such studies
progress to completion. Revisions are charged to expense in the
period in which the facts that give rise to the revision become
known. At December 31, 2011 and 2010 we had accrued $28 thousand
and $0.3 million, respectively of CRO and clinical trial study
expenses.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -16.6pt; MARGIN: 0px 0px 0px 31pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;9. Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
We account for income taxes under the liability method. Under this
method, deferred income tax assets and liabilities are determined
based on differences between the financial reporting and the income
tax basis of assets and liabilities and are measured using the
enacted income tax rates and laws that will be in effect when the
differences are expected to reverse. Additionally, net operating
loss and tax credit carryforwards are reported as deferred income
tax assets. The realization of deferred income tax assets is
dependent upon future earnings. A valuation allowance is required
against deferred income tax assets if, based on the weight of
available evidence, it is more likely than not that some or all of
the deferred income tax assets may not be realized. During 2009 we
determined it was more likely than not that we would not be able to
realize our recorded deferred income tax assets and we recorded an
adjustment of $2.5 million to the deferred income tax asset
valuation allowance and recognized an expense from income taxes in
such period. At both December 31, 2011 and 2010, 100% of all
remaining net deferred income tax assets were offset by a valuation
allowance due to uncertainties with respect to future utilization
of net operating loss carryforwards. If in the future it is
determined that additional amounts of our deferred income tax
assets would likely be realized, the valuation allowance would be
reduced in the period in which such determination is made and an
additional benefit from income taxes in such period would be
recognized.&lt;/p&gt;
&lt;p style="TEXT-INDENT: -16.6pt; MARGIN: 0px 0px 0px 31pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -16.6pt; MARGIN: 0px 0px 0px 31pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;10. Earnings (Loss) Per Share&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The computation of basic earnings (loss) per share of common stock
is based upon the weighted average number of common shares
outstanding during the period, including shares weighted related to
vested RSUs (See Note G). The computation of diluted earnings
(loss) per share is based on the same number of shares used in the
basic share calculation adjusted for the effect of other
potentially dilutive securities. No such adjustments were made for
2010 or 2009 as their effects would have been antidilutive.&lt;/p&gt;
&lt;table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="8"&gt;
Year&amp;#xA0;ended&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt" colspan="9"&gt;(in
thousands except per share data)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;Basic
earnings per share&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in; WIDTH: 64%"&gt;
Net &amp;#xA0;income (loss) applicable to common stockholders&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
10,385&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
(12,707&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
(15,835&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Denominator:&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 0.25in"&gt;Common shares&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;45,016&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;43,842&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;42,912&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in"&gt;Vested
RSUs&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,480&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,187&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,020&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;Weighted average
number of shares outstanding&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
47,496&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
47,029&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
45,932&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Basic earnings (loss) per common share&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.22&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.27&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.35&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;Diluted
earnings (loss) per share&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Denominator:&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 0.25in"&gt;Common shares&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;45,016&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;43,842&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;42,912&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 0.25in"&gt;Vested RSUs&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,489&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,187&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,020&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in"&gt;Stock
options&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;366&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in"&gt;
Common stock warrants&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
136&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;Weighted average
number of shares outstanding&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
48,007&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
47,029&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
45,932&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Diluted earnings (loss) per common share&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.22&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.27&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.35&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Excluded potentially dilutive securities:&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Common stock
issuable (1):&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in"&gt;Stock
options&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,805&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,243&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,671&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in"&gt;Common stock
warrants&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,193&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,380&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in"&gt;RSUs&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
49&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
204&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Total excluded dilutive shares&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,805&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
6,485&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
6,255&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 90%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: justify; WIDTH: 100%; TEXT-AUTOSPACE: ideograph-numeric"&gt;
(1) The number of shares is based on maximum number of shares
issuable on exercise or conversion of the related securities as of
our year end. Such amounts have not been adjusted for the treasury
stock method or weighted average outstanding calculations as
required if the securities were dilutive.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-INDENT: -16.6pt; MARGIN: 0px 0px 0px 31pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: -16.6pt; MARGIN: 0px 0px 0px 31pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;11. Share-Based Compensation&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
We have four share-based compensation plans covering stock options
and RSUs for our employees and directors, which are described more
fully in Note G.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
We measure our compensation cost related to share-based payment
transactions based on fair value of the equity or liability
instrument issued. For purposes of estimating the fair value of
each stock option unit on the date of grant, we utilize the
Black-Scholes option-pricing model. The Black-Scholes option
valuation model was developed for use in estimating the fair value
of traded options, which have no vesting restrictions and are fully
transferable. In addition, option valuation models require the
input of highly subjective assumptions including the expected
volatility factor of the market price of our common stock (as
determined by reviewing our historical public market closing
prices).&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Our accounting for share-based compensation for RSUs is based on
the fair-value method. The fair value of the RSUs is the market
price of our common stock on the date of grant, less its exercise
cost.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.7in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Our non-cash share-based compensation expenses comprised the
following:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="10"&gt;Year Ended December 31,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="9"&gt;(in thousands)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Research and development&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt; WIDTH: 64%"&gt;Stock
options&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;457&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,419&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,702&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;RSUs&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
75&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
279&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
203&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
532&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,697&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,905&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;General and administrative&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Stock options&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,698&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,365&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6,539&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;RSUs&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
228&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
684&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
760&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,926&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
5,049&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
7,299&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;Total&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,458&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
6,746&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
9,204&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">217000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE E &amp;#x2013; COMMON STOCK WARRANTS&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The Company has outstanding common stock purchase warrants at
December 31, 2011 exercisable for 1.9 million shares of common
stock, all of which contain a cashless exercise feature. These
warrants have an exercise price of $3.40 per share and expiration
date of August 2014.&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-131000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">32000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-2000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncomeTaxesPaid contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">284000</us-gaap:IncomeTaxesPaid>
  <us-gaap:Revenues contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">20466000</us-gaap:Revenues>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE H &amp;#x2013; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Securities Class Action and Derivative Litigation&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
A lawsuit captioned &lt;i&gt;Bang v. Acura Pharmaceuticals, et al&lt;/i&gt;,
was filed on September 10, 2010 in the United States District Court
for the Northern District of Illinois, Eastern Division (Case
1:10-cv-05757) against us and certain of our current and former
officers seeking unspecified damages on behalf of a putative class
of persons who purchased our common stock (the &amp;#x201C;Affected
Securities&amp;#x201D;) between February 21, 2006 and April 22, 2010
(the &amp;#x201C;Plaintiff Class&amp;#x201D;). The complaint alleged that
certain Company officers made false or misleading statements, or
failed to disclose material facts in order to make statements not
misleading, relating to our Acurox&lt;sup&gt;&amp;#xAE;&lt;/sup&gt; with Niacin
Tablet product candidate, resulting in violations of Section 10(b)
of the Securities Exchange Act of 1934 (the &amp;#x201C;Exchange
Act&amp;#x201D;), Rule 10b-5 under the Exchange Act and Section 20(a) of
the Exchange Act. The complaint further alleges that such false or
misleading statements or omissions had the effect of artificially
inflating the price of our common stock. On March 14, 2011, an
amended complaint was filed in this lawsuit.&amp;#xA0; The amended
complaint asserts the same claims as the initial complaint based
upon the same alleged false or misleading statements, and has added
three of our current directors as defendants.&amp;#xA0; The Court has
changed the caption of this case to &lt;i&gt;In re Acura Pharmaceuticals,
Inc. Securities Litigation&lt;/i&gt;. We filed a motion to dismiss this
case on May 13, 2011.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: -1in; MARGIN: 0px 0px 0px 1in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
On October 31, 2011, we entered into a Stipulation of Settlement
(&amp;#x201C;Stipulation&amp;#x201D;) providing for the release of all claims
against the Company and its named directors and officers (the
&amp;#x201C;Defendants&amp;#x201D;) in this case, for a payment of $1.5
million. The Company and the individual defendants continue to deny
all charges of wrongdoing or liability against them relating to
this action and the Stipulation does not contain or constitute any
admission or finding of wrongful conduct, acts or omissions on the
part of any Defendant. On December 16, 2011 our insurance carrier
paid the $1.5 million settlement amount into an escrow account to
fund the settlement.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
In consideration of the payment of the settlement amount, the
Plaintiff Class has agreed, upon final approval by the court, to
dismiss the class action with prejudice and release all known and
unknown claims arising out of or relating to, or in connection with
the purchase or acquisition of the Affected Securities during the
class period which have been or could have been asserted by the
members of the Plaintiff Class. On February 16, 2012, the court
entered final approval of the settlement reflected in the
Stipulation.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
On October 25, 2010, Kiley Hill, a purported stockholder of the
Company filed a shareholder derivative action in the Circuit Court
of Cook County, Illinois, Chancery Division captioned &lt;i&gt;Hill v.
Acura Pharmaceuticals&lt;/i&gt; et al. (Case No. 2010-CH-46380), against
our directors and certain of our executive officers, generally
relating to the same events that are the subject of the class
action litigation described above. The complaint purports to be
brought on our behalf and names us as a nominal defendant. The
complaint seeks unspecified damages from the individual defendants
for breaches of fiduciary duty, abuse of control, gross
mismanagement, contribution and indemnification, waste of corporate
assets and unjust enrichment for actions occurring from at least
February 21, 2006 through April 22, 2010. Substantively similar
complaints captioned &lt;i&gt;Hagan v. Acura Pharmaceuticals&lt;/i&gt; et al.
(Case No. 2010-CH-46621) and &lt;i&gt;Newell v. Reddick&lt;/i&gt; et al (Case
No. 2010-CH-46873) were filed in the Circuit Court of Cook County,
Illinois, Chancery Division, by other purported stockholders of the
Company on October 27, 2010 and October 28, 2010, respectively. We
filed a notion to dismiss these shareholder derivative actions on
November 23, 2011.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px"&gt;
&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Reglan&lt;/b&gt;&amp;#xAE;&lt;b&gt;/Metoclopramide Litigation&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Halsey Drug Company, as predecessor to us, has been named along
with numerous other companies as a defendant in cases filed in
three separate state coordinated litigations pending in
Pennsylvania, New Jersey and California, respectively captioned In
re: Reglan&amp;#xAE;/Metoclopramide Mass Tort Litigation, Philadelphia
County Court of Common Pleas, January Term, 2010, No. 01997; In re:
Reglan&amp;#xAE; Litigation, Superior Court of New Jersey, Law
Division, Atlantic County, Case No. 289, Master Docket No.
ATL-L-3865-10; and Reglan&amp;#xAE;/Metoclopramide Cases, Superior
Court of California, San Francisco County, Judicial Council
Coordination Proceeding No. 4631, Superior Court No.:
CJC-10-004631.&amp;#xA0; In this product liability litigation against
numerous pharmaceutical product manufacturers and distributors,
including us, plaintiffs claim injuries from their use of the
Reglan brand of metoclopramide and generic metoclopramide.&amp;#xA0; In
the Pennsylvania state court mass tort proceeding, over 200
lawsuits have been filed against us and Halsey Drug Company
alleging that plaintiffs developed neurological disorders as a
result of their use of the Reglan brand and/or generic
metoclopramide.&amp;#xA0; Plaintiffs have filed approximately 150
lawsuits against us, but have served less than 50 individual
lawsuits upon us in the New Jersey action. In the California
action, we were not served with any complaints until the Spring of
2011 when a single complaint including over 400 plaintiffs was
served.&amp;#xA0; To date, Acura has not been served with any
metoclopramide lawsuits in jurisdictions other than Philadelphia,
New Jersey and California state courts.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
In the lawsuits filed to date, plaintiffs have not confirmed they
ingested any of the generic metoclopramide manufactured by
us.&amp;#xA0; We discontinued manufacture and distribution of generic
metoclopramide more than 15 years ago.&amp;#xA0; In addition, we
believe the June 23, 2011 decision by the U.S. Supreme Court in
&lt;i&gt;PLIVA v. Mensing (&amp;#x201C;Mensing&lt;/i&gt; decision&amp;#x201D;) holding
that state tort law failure to warn claims against generic drug
companies are pre-empted by the 1984 Hatch-Waxman Act Amendments
and federal drug regulations will assist us in favorably resolving
these cases. We have consistently maintained the position that
these claims are without merit and intend to vigorously defend
these actions.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.7in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
In Philadelphia, New Jersey and California, Generic Defendants,
including Acura, have filed dispositive motions based on the
&lt;i&gt;Mensing&lt;/i&gt; decision. The New Jersey and California courts are
expected to issue their rulings later this year. On November 18,
2011, the Philadelphia trial court denied Generic Defendants&amp;#x2019;
dispositive motion. In December 2011, the Generic Defendants
appealed this ruling, which the trial court refused to modify on
reconsideration. Nonetheless, the trial court has approved
certification of the federal preemption issues based on the
&lt;i&gt;Mensing&lt;/i&gt; decision for immediate appeal to the Pennsylvania
Superior Court. A decision on this appeal should be issued later
this year which could result in dismissal of all of the
Philadelphia cases against Generic Defendants, although there can
be no assurance in this regard. As any potential loss is neither
probable or estimable, we have not accrued for any potential loss
related to this matter as of December 31, 2011. Legal fee related
to this matter are currently covered by our insurance carrier.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Statutory Minimum Withholding Tax Obligations&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Under our stock option plans and our 2005 RSU plan, our employees
may elect to have shares withheld upon exercise of options and upon
the exchange of RSUs in satisfaction of the statutory minimum
withholding tax obligations of such employees relating to such
option exercises or RSU exchanges. During 2011, elections were made
to have 0.29 million of common shares withheld by the Company upon
the exchange of RSUs in satisfaction of $1.0 million in withholding
tax obligations and other elections were made to have 0.23 million
common shares withheld by the Company upon the exercise of options
in satisfaction of $0.9 million in withholding tax obligations. On
January 1, 2012, elections were made to have 0.29 million of common
shares withheld by the Company upon the exchange of RSUs in
satisfaction of $1.1 million in withholding tax obligations.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Financial Advisor Agreement&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
In connection with our August 2007 Unit Offering, we are obligated
to pay a fee to our then financial advisor upon each exercise of
the warrants issued in the Unit Offering, in proportion to the
number of warrants exercised. The amount of the fee assuming 100%
exercise of the remaining 1.9 million warrants is $0.38 million. We
have not reflected this obligation as a liability in our
consolidated financial statements as the payment is contingent upon
the timing and exercise of the warrants by each of the warrant
holders. Such fee, if any, will be paid to the financial advisor
and be offset against the equity proceeds as the warrants are
exercised.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CostsAndExpenses contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">9932000</us-gaap:CostsAndExpenses>
  <us-gaap:ProceedsFromWarrantExercises contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1076000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">12312000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:GainLossOnDispositionOfAssets contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-8000</us-gaap:GainLossOnDispositionOfAssets>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ReimbursementRevenue>
  <us-gaap:OtherNonoperatingExpense contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">34000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">10532000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">2458000</us-gaap:ShareBasedCompensation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.22</us-gaap:EarningsPerShareDiluted>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-209000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1839000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">217000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">10385000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-126000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">4037000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE I &amp;#x2013; SELECTED QUARTERLY FINANCIAL DATA
(UNAUDITED)&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="11"&gt;Three&amp;#xA0;Month&amp;#xA0;Period&amp;#xA0;Ended&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="11"&gt;&amp;#xA0;(in thousands
except per share data)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt;
Calendar&amp;#xA0;Year&amp;#xA0;2011&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Mar.&amp;#xA0;31&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Jun.&amp;#xA0;30&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Sept.&amp;#xA0;30&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Dec.&amp;#xA0;31&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 52%"&gt;Total revenue (i)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;233&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;20,233&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Income (loss) from operations&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(2,834&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;17,362&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(2,147&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(1,847&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Net income
(loss)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(2,857&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
17,029&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(2,141&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(1,646&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Income (loss) per common share&amp;#xA0;
Basic&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(0.06&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0.36&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(0.05&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(0.03&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;Diluted&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.06&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0.35&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.05&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.03&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px"&gt;&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0px; WIDTH: 52%"&gt;
Calendar Year 2010&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 10%"&gt;
Mar. 31&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 10%"&gt;
Jun. 30&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 10%"&gt;
Sept. 30&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; WIDTH: 10%"&gt;
Dec. 31&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Total revenue (i)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,040&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;620&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;292&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;359&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Loss from operations&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(4,035&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(3,186&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(2,566&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(2,937&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Net loss&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(4,035&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(3,192&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(2,553&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(2,927&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Loss per common
share - basic and diluted&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.09&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.07&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.05&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(0.06&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.25in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&amp;#xA0; (i) See Note A(7) for revenue recognition.&lt;/p&gt;
&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">131000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2">0.22</us-gaap:EarningsPerShareBasic>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">131000</us-gaap:DepreciationAndAmortization>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">10534000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">53000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE C &amp;#x2013; PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.2in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Property, plant and equipment are summarized as follows:&lt;/p&gt;
&lt;table style="WIDTH: 70%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="5"&gt;December&amp;#xA0;31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;(in thousands)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt; WIDTH: 76%"&gt;
Building and improvements&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,252&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;1,243&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;Land
and improvements&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;162&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;161&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Machinery and equipment&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;117&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;43&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Scientific equipment&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;583&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;583&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Computer hardware and software&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;270&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;251&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Office equipment&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;27&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;27&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Other personal property&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
70&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
68&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,481&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;2,375&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Less accumulated depreciation and amortization&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(1,437&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(1,323&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Total property,
plant and equipment, net&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,044&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
1,052&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Depreciation and amortization expense was approximately $0.1
million for each of the years ended December 31, 2011, 2010, and
2009. We lease administrative offer space in Palatine Illinois
under a lease expiring March 31, 2013 for approximately $29
annually.&lt;/p&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">5895000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">147000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">11640000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="shares" decimals="-3">47496000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">33000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE F &amp;#x2013; INCOME TAXES&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.3in; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Provision for Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The reconciliation between our provision for income taxes and the
amounts computed by multiplying our income (loss) before taxes by
the U.S. statutory tax rate is as follows&lt;font style="COLOR: black"&gt;:&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 80%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="8"&gt;December&amp;#xA0;31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="8"&gt;(in thousands)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt; WIDTH: 64%"&gt;
Tax (benefit) at U.S. statutory 34% &amp;#xA0;tax rate&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;3,510&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;(4,320&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;(4,541&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
State taxes (benefit), net of federal effect&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(56&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(416&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Research and development tax credits&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(77&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(45&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(100&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;Wage
reported share-based compensation&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(307&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(587&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Stock compensation&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;626&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;-&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;Other&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(362&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(315&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(330&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Change in valuation allowance&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(3,863&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
4,748&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
8,453&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Provision for
income taxes&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
147&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
11&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,479&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.3in; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Tax expense for 2011 is federal alternative minimum taxes
(&amp;#x201C;AMT&amp;#x201D;) and current state taxes. The tax expense for
2010 is current state taxes and for 2009 it is deferred taxes.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.3in; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.3in; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Deferred Tax Assets and Valuation Allowance&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
Deferred tax assets reflect the tax effects of net operating losses
(&amp;#x201C;NOLs&amp;#x201D;), tax credit carryovers, and temporary
differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income
tax purposes. The most significant item of our deferred tax assets
is derived from our Federal NOLs. We have approximately $23.0
million federal income tax benefits at December 31, 2011 derived
from $67.6 million Federal NOLs at the U.S. statutory tax rate of
34%, available to offset future taxable income, some of which have
limitations for use as prescribed under IRC Section 382. Our NOLs
will expire in varying amounts between 2012 and 2030 if not used,
and those expirations will cause fluctuations in our valuation
allowances. The components of our deferred tax assets are as
follows:&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 70%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="5"&gt;December 31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="5"&gt;(in thousands)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 2.35pt"&gt;Deferred tax
assets:&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Estimated future value of NOLs&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt; WIDTH: 76%"&gt;- Federal&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;22,963&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;25,101&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;- State&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,179&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3,260&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Research and
development tax credits&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;887&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;234&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt"&gt;Deferred program
fee revenue&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;183&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Share-based compensation&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4,628&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;7,704&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;Other,
net&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(8&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
30&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-LEFT: 0.25in"&gt;Total deferred
taxes&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;32,649&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;36,512&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 2.35pt"&gt;
Valuation allowance&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(32,649&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(36,512&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 0.25in"&gt;Net
deferred tax assets&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Realization of deferred tax assets is dependent upon future
earnings, if any, and the timing and amount of which may be
uncertain. Valuation allowances are placed on deferred tax assets
when uncertainty exists on their near term utilization. We make
periodic reviews of our valuation allowances and fluctuations can
occur. Those fluctuations may be reflected as income tax expenses
or benefits in the period they occur. In 2009, we increased the
valuation allowance by $2.5 million for the then available deferred
tax assets and also placed a valuation allowance against the 2009
and 2010 operating results. In 2011 we decreased our valuation
allowance to utilize the NOLs to offset our taxable income from our
2011 operating results; however we still incurred an AMT liability.
We continue to maintain full valuation allowance against all of our
deferred tax assets at December 31, 2011 due to uncertainties with
respect to future utilization of net operating loss carryforwards.
If in the future it is determined that amounts of our deferred tax
assets would likely be realized, the valuation allowance would be
reduced in the period in which such determination is made and a
benefit from income taxes in such period would be recognized.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.3in; MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Uncertainty in Income Taxes&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
We adopted FASB&amp;#x2019;s statement regarding accounting for
uncertainty in income taxes which defined the threshold for
recognizing the benefits of tax-return positions in the financial
statements as "more-likely-than-not" to be sustained by the taxing
authorities. Our adoption of the standard did not result in
establishing a contingent tax liability reserve or a corresponding
charge to retained earnings. At each of December 31, 2011, 2010 and
2009, we had no liability for income tax associated with uncertain
tax positions. If in the future we establish a contingent tax
liability reserve related to uncertain tax positions, our practice
will be to recognize the interest in interest expense and the
penalties in other non-operating expense.&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:InterestPaid contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">26000</us-gaap:InterestPaid>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE D &amp;#x2013; ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-INDENT: 0.2in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
Accrued expenses are summarized as follows:&lt;/p&gt;
&lt;table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="5"&gt;December 31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="5"&gt;(in thousands)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt; WIDTH: 76%"&gt;
Payroll, payroll taxes and benefits&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;104&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;95&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Professional services&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;191&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;193&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Franchise taxes&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;60&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;12&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Property taxes&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;21&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;19&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Clinical and regulatory services&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;59&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;307&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; TEXT-INDENT: -5.05pt; PADDING-LEFT: 5.05pt"&gt;
Other fees and services&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
42&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
60&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
477&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
686&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE G &amp;#x2013; EMPLOYEE BENEFIT PLANS&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;401(k) and Profit-Sharing Plan&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
We have a 401(k) and Profit-Sharing Plan (the &amp;#x201C;Plan&amp;#x201D;)
for our employees. Employees may elect to make a basic contribution
of up to 15% of their annual earnings. The Plan provides that the
Company can make discretionary matching contributions equal to 25%
of the first 6% of employee contributions for an aggregate employee
contribution of 1.5%, along with a discretionary profit-sharing
contribution. We did not contribute matching or profit sharing
contributions for the Plan in years 2011, 2010, and 2009.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Stock Option Plans&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
We maintain various stock option plans. &lt;font style="COLOR: black"&gt;A summary of our stock option plans as of
December&amp;#xA0;31, 2011, 2010, and 2009, and for the years then
ended consisted of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 80%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="17"&gt;Years&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="17"&gt;(in thousands except
per share data)&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&lt;br /&gt;
Options&lt;br /&gt;
(000&amp;#x2019;s)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&lt;br /&gt;
Options&lt;br /&gt;
(000&amp;#x2019;s)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&lt;br /&gt;
Options&lt;br /&gt;
(000&amp;#x2019;s)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Exercise&lt;br /&gt;
Price&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 28%"&gt;
Outstanding, beginning&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
4,243&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
5.40&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3,671&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
5.90&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
2,968&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
4.93&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Granted&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;491&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.63&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;649&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.36&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1,312&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.38&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Exercised&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(1,102&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1.33&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(525&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;1.30&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;
Forfeited or expired&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(76&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3.15&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(77&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
10.10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(84&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
7.95&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;Outstanding, ending&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,556&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
6.41&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
4,243&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
5.40&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,671&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
5.90&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;Options
exercisable&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,962&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
7.01&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,528&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
5.71&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,712&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
5.49&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
The following table summarizes information about nonvested stock
options outstanding at December&amp;#xA0;31, 2011:&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.2in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;table style="WIDTH: 60%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&amp;#xA0;of&lt;br /&gt;
Options&lt;br /&gt;
Not&lt;br /&gt;
Exercisable&lt;br /&gt;
(000)&amp;#x2019;s&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Weighted&lt;br /&gt;
Average&lt;br /&gt;
Fair&lt;br /&gt;
Value&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="5"&gt;(in thousands except per
share data)&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="WIDTH: 76%"&gt;
Outstanding&amp;#xA0;at&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2010&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
715&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; WIDTH: 1%"&gt;
$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3.64&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Granted&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;491&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.39&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Vested&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(546&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;4.18&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Forfeited&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(66&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3.02&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
594&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3.22&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
We estimate the option&amp;#x2019;s fair value on the date of grant
using the Black-Scholes option-pricing model. Black-Scholes
utilizes assumptions related to volatility, the risk-free interest
rate, the dividend yield (which is assumed to be zero, as we have
not paid any cash dividends) and employee exercise behavior.
Expected volatilities utilized in the Black-Scholes model are based
on the historical volatility of our common stock price. The
risk-free interest rate is derived from the U.S. Treasury yield
curve in effect at the time of grant. The expected life of the
grants is derived from historical exercise activity. Historically,
our stock options have been held until their expiration date. The
assumptions used in the Black-Scholes model to determine fair value
for the 2011, 2010 and 2009 stock option grants were:&lt;/p&gt;
&lt;table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 64%"&gt;Expected dividend
yield&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;0.0%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;0.0%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right; WIDTH: 10%"&gt;0.0%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; WIDTH: 1%"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Risk-free interest rates&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;1.9% to 3.4%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;3.5% to 3.9%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" nowrap="nowrap"&gt;2.4% to 3.1%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Average expected&amp;#xA0; volatility&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;114%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;119%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;124%&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left"&gt;Expected term (years)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;10&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;Weighted average grant date fair value&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.39&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;3.18&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;$&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;6.06&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px 0px 0px 13.7pt; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
As of December 31, 2011, 2010, and 2009 the aggregate intrinsic
value of the option awards vested was $0.3 million, $2.4 million
and $4.8 million, respectively. In addition, the aggregate
intrinsic value of option awards exercised during the year ended
December 31, 2011 and 2009 was $2.7 million and $1.7 million,
respectively. There were no options exercised in 2010. The total
remaining unrecognized compensation cost related to the unvested
option awards at December 31, 2011 was $2.0 million and is expected
to be recognized in varying amounts over the 23 months remaining in
the requisite service period. During 2011 options to purchase 935
shares of common stock were exercised utilizing various cashless
exercise features of our stock option plan and after withholding
shares for $887 in statutory minimum payroll taxes and $1,252 in
exercise costs, we issued 381 shares of common stock. During 2009
options to purchase 525 shares of common stock were exercised in
cashless exercise transactions and after withholding shares for
statutory minimum payroll taxes calculated at $685, we issued 225
shares of common stock.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;&amp;#xA0;&lt;/b&gt;&lt;/p&gt;
&lt;p style="MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;Restricted Stock Unit Award Plan&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
We have a Restricted Stock Unit Award Plan (&amp;#x201C;2005 RSU
Plan&amp;#x201D;) for our employees and non-employee directors. Vesting
of an RSU entitles the holder to receive a share of common stock of
the Company on a distribution date. &lt;font style="COLOR: black"&gt;A
summary of the RSU Plan as of December&amp;#xA0;31, 2011, 2010, and
2009, and for the years then ended consisted of the
following:&lt;/font&gt;&lt;/p&gt;
&lt;table style="WIDTH: 90%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="17"&gt;Years&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;2011&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;2010&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="5"&gt;2009&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: center" colspan="17"&gt;(in
thousands)&amp;#xA0;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="VERTICAL-ALIGN: bottom"&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&amp;#xA0;RSUs&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&amp;#xA0;Vested&lt;br /&gt;
RSUs&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&amp;#xA0;RSUs&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&amp;#xA0;Vested&lt;br /&gt;
RSUs&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&lt;br /&gt;
RSUs&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"&gt;Number&lt;br /&gt;
of&amp;#xA0;Vested&lt;br /&gt;
RSUs&lt;/td&gt;
&lt;td&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 28%"&gt;
Outstanding, beginning&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3,316&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3,267&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3,316&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3,112&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
3,000&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right; WIDTH: 10%"&gt;
2,970&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; WIDTH: 1%"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Granted&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;330&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Distributed&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(829&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;(829&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;)&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-LEFT: 9pt"&gt;Vested&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;49&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;155&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right"&gt;142&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt"&gt;
Forfeited or expired&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
(17&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;)&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
0&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"&gt;
&lt;td style="PADDING-BOTTOM: 1pt"&gt;Outstanding, ending&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,487&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
2,487&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,316&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,267&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,316&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
&amp;#xA0;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"&gt;
3,112&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The share-based compensation cost to be incurred on the RSUs is the
RSU&amp;#x2019;s fair value, which is the market price of the
Company&amp;#x2019;s common stock on the date of grant, less its
exercise cost. The fair value of the RSU grants made in 2009 and
2008 was $2.1 million and $0.4 million, respectively. The weighted
average fair value of a RSU outstanding at December 31, 2011 is
$3.83.&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The 2005 RSU Plan provides that upon a change in control of the
Company or upon termination of an employee&amp;#x2019;s employment with
the Company without cause, vesting will accelerate and the RSUs
will fully vest. Absent a change of control, one-fourth of vested
shares of common stock underlying an RSU award will be distributed
(after payment of $0.01 par value per share) on January 1 of each
of 2011, 2012, 2013 and 2014. If a change in control occurs, the
vested shares underlying the RSU award will be distributed at or
about the time of the change in control. &lt;font style="COLOR: black"&gt;On January 1, 2011, 0.54 million vested shares were
distributed to the holders while 0.29 million shares were withheld
by the Company upon elections made to exchange RSUs in satisfaction
of $1.0 million withholding tax obligations. On January 1, 2012,
0.54 million vested shares were distributed to the holders while
0.29 million shares were withheld by the Company upon elections
made to exchange RSUs in satisfaction of $0.9 million withholding
tax obligations.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-466000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="shares" decimals="-3">48007000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">-541000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">1076000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:ResearchAndDevelopmentDisclosureTextBlock contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0">&lt;div&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;b&gt;NOTE B &amp;#x2013; LICENSE, DEVELOPMENT, AND COMMERCIALIZATION
AGREEMENT&lt;/b&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="LETTER-SPACING: -0.1pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="LETTER-SPACING: -0.1pt"&gt;On October 30, 2007, we and
King Pharmaceuticals Research and Development, Inc., now a
wholly-owned subsidiary of Pfizer, entered into the Pfizer
Agreement to develop and commercialize in the United States, Canada
and Mexico certain opioid analgesic products utilizing our
proprietary Aversion Technology. The Pfizer Agreement initially
provided Pfizer with an exclusive license in the United States,
Canada and Mexico, or the Pfizer Territory, for Oxecta (oxycodone
HCl) Tablets and oxycodone HCl/acetaminophen tablets utilizing
Aversion Technology. In addition, the Pfizer Agreement provides
Pfizer with an option to license in the Pfizer Territory certain
future opioid analgesic products developed utilizing Aversion
Technology. As of December 31, 2011, Pfizer exercised its option to
license two additional product candidates including an undisclosed
immediate-release opioid analgesic tablet product and hydrocodone
bitartrate/acetaminophen tablets, each of which utilize our
Aversion Technology. The Pfizer Agreement provides that we or
Pfizer may develop additional opioid analgesic product candidates
utilizing our Aversion Technology and, if Pfizer exercises its
option to license such additional product candidates, they will be
subject to the milestone and royalty payments and other terms of
the Pfizer Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="LETTER-SPACING: -0.1pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="LETTER-SPACING: -0.1pt"&gt;As of December 31, 2011, we
had received aggregate payments of $78.5 million from Pfizer,
consisting of a $30.0 million non-refundable upfront cash payment,
$17.5 million in reimbursed research and development expenses
relating to licensed products, $6.0 million in fees relating to
Pfizer&amp;#x2019;s exercise of its option to license an undisclosed
immediate-release opioid analgesic tablet product and hydrocodone
bitartrate/acetaminophen tablets, a $5.0 million milestone fee
relating to our successful achievement of the primary endpoints for
our pivotal Phase III clinical study for Aversion oxycodone HCl
with niacin tablets and a $20.0 million milestone fee relating to
the FDA&amp;#x2019;s approval of the Oxecta Tablets NDA. The Pfizer
Agreement also provides for Pfizer&amp;#x2019;s payment to us of a $3.0
million fee upon Pfizer&amp;#x2019;s exercise of its option for each
future opioid analgesic utilizing Aversion Technology. In the event
that Pfizer does not exercise its option for a Future Product,
Pfizer may be required to reimburse us for certain of our expenses
relating to such Future Product. Further, we may receive up to $23
million in additional non-refundable milestone payments for each
active opioid analgesic ingredient licensed to Pfizer which
achieves certain regulatory milestones in specific countries in the
Pfizer Territory. An opioid analgesic product candidate formulated
with and without niacin is considered a single product candidate
for purposes of the option fees and milestone payments payable
under the Pfizer Agreement. We can also receive a one-time $50
million sales milestone payment upon the first attainment of $750
million in net sales of all of our licensed products across all
Pfizer Territories. In addition,&lt;/font&gt; &lt;font style="COLOR: black"&gt;for sales occurring on and following February 2,
2013 (the one year anniversary of the first commercial sale of
Oxecta),&lt;/font&gt; &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt;&lt;font style="COLOR: black"&gt;will pay us a royalty at one of six rates ranging
from 5% to 25% based on the level of combined annual net sales for
all products licensed by us to&lt;/font&gt; &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt; &lt;font style="COLOR: black"&gt;across all&lt;/font&gt; &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt;&lt;font style="COLOR: black"&gt;Territories, with the highest applicable royalty
rate applied to such combined annual sales.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&amp;#xA0;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt;&lt;font style="COLOR: black"&gt;&amp;#x2019;s royalty payment obligations expire on a
product-by-product and country-by-country basis upon the later of
(i) the expiration of the last valid patent claim covering such
product in such country, or (ii) 15 years from the first commercial
sale of such product in such country. No minimum annual fees are
payable by either party under the&lt;/font&gt; &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt;&lt;font style="COLOR: black"&gt;Agreement. If Pfizer, after consultation with us,
enters into a license agreement with a third party to avoid or
settle such third party&amp;#x2019;s allegations or claims regarding
freedom to operate against a licensed Aversion Technology product,
Pfizer may deduct 50% of any royalties or other license payments it
pays to such third party under such license, provided that the
royalties payable to us are no less than 80% of the royalties
otherwise due to us under the Pfizer Agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
&lt;font style="LETTER-SPACING: -0.1pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;
&lt;p style="TEXT-ALIGN: justify; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"&gt;
The &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt; Agreement
expires upon the expiration of &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt;&amp;#x2019;s royalty payment and
other payment obligations under the &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt; Agreement. &lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt; may terminate the
&lt;font style="LETTER-SPACING: -0.1pt"&gt;Pfizer&lt;/font&gt; Agreement (i) in
its entirety at any time by written notice to us, and (ii) with
respect to any product at any time upon the provision of not less
than 12 months&amp;#x2019; prior written notice&lt;font style="LETTER-SPACING: -0.1pt"&gt;. We may terminate the Pfizer Agreement
with respect to a product in the United States in the event such
product is not commercially launched by Pfizer within 120 days
after receipt of regulatory approval of such product or in its
entirety if Pfizer commences any interference or opposition
proceeding challenging the validity or enforceability of any of our
patent rights licensed to Pfizer under the Pfizer Agreement. Either
party has the right to terminate the Pfizer Agreement on a product
by product and country-by-country basis if the other party is in
material breach of its obligations under the Pfizer Agreement
relating to such product and such country, and to terminate the
Agreement in its entirety in the event the other party makes an
assignment for the benefit of creditors, files a petition in
bankruptcy or otherwise seeks relief under applicable bankruptcy
laws, in each case subject to applicable cure periods.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</acur:ResearchAndDevelopmentDisclosureTextBlock>
  <acur:ProgramFeeRevenue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0" unitRef="iso4217_USD" decimals="-3">466000</acur:ProgramFeeRevenue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">10385000</us-gaap:NetIncomeLoss>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">0</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920_455296x441133" unitRef="iso4217_USD" decimals="-3">0</acur:SharesWithheldForTaxValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920_455296x477835" unitRef="iso4217_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920_455296x477835" unitRef="iso4217_USD" decimals="-3">0</acur:SharesWithheldForTaxValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="-3">167000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="-3">828000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">8000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">0</us-gaap:NetIncomeLoss>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">3000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="-3">336000</acur:StockIssuedDuringPeriodSharesStockWarrantsExercised>
  <acur:AdjustmentsToAdditionalPaidInCapitalShare-BasedCompensationRequisiteServicePeriodRecognitionShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581" unitRef="shares" decimals="-3">0</acur:AdjustmentsToAdditionalPaidInCapitalShare-BasedCompensationRequisiteServicePeriodRecognitionShares>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x441133" unitRef="iso4217_USD" decimals="-3">3000</acur:SharesWithheldForTaxValue>
  <acur:SharesWithheldForTaxShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x441133" unitRef="shares" decimals="-3">288000</acur:SharesWithheldForTaxShares>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x477835" unitRef="shares" decimals="-3">611000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x477835" unitRef="iso4217_USD" decimals="-3">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x477835" unitRef="iso4217_USD" decimals="-3">2000</acur:SharesWithheldForTaxValue>
  <acur:SharesWithheldForTaxShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x477835" unitRef="shares" decimals="-3">228000</acur:SharesWithheldForTaxShares>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">2458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">-8000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">215000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">0</us-gaap:NetIncomeLoss>
  <acur:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">1073000</acur:StockIssuedDuringPeriodValueStockWarrantsExercised>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698_455296x441133" unitRef="iso4217_USD" decimals="-3">945000</acur:SharesWithheldForTaxValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698_455296x477835" unitRef="iso4217_USD" decimals="-3">-6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698_455296x477835" unitRef="iso4217_USD" decimals="-3">884000</acur:SharesWithheldForTaxValue>
  <acur:SupplementalTaxWithholding contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133" unitRef="iso4217_USD" decimals="-3">948000</acur:SupplementalTaxWithholding>
  <acur:CommonStockIssuedShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133" unitRef="shares" decimals="-3">540000</acur:CommonStockIssuedShares>
  <acur:EquityBasedEmployeeCompensationGrantedShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133" unitRef="shares" decimals="-3">829000</acur:EquityBasedEmployeeCompensationGrantedShares>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133" unitRef="iso4217_USD" decimals="-3">948000</acur:SharesWithheldForTaxValue>
  <acur:EquityIssuanceCostsWithheld contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133" unitRef="iso4217_USD" decimals="-3">3000</acur:EquityIssuanceCostsWithheld>
  <acur:SharesWithheldToSatisfyEmployeesTaxWithholdingShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133" unitRef="shares" decimals="-3">288000</acur:SharesWithheldToSatisfyEmployeesTaxWithholdingShares>
  <acur:SupplementalTaxWithholding contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864" unitRef="iso4217_USD" decimals="-3">886000</acur:SupplementalTaxWithholding>
  <acur:CommonStockIssuedShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864" unitRef="shares" decimals="-3">383000</acur:CommonStockIssuedShares>
  <acur:EquityBasedEmployeeCompensationGrantedShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864" unitRef="shares" decimals="-3">935000</acur:EquityBasedEmployeeCompensationGrantedShares>
  <acur:CommonStockWithheldShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864" unitRef="shares" decimals="-3">324000</acur:CommonStockWithheldShares>
  <acur:EquityIssuanceCostsWithheld contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864" unitRef="iso4217_USD" decimals="-3">1252000</acur:EquityIssuanceCostsWithheld>
  <acur:SharesWithheldToSatisfyEmployeesTaxWithholdingShares contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864" unitRef="shares" decimals="-3">230000</acur:SharesWithheldToSatisfyEmployeesTaxWithholdingShares>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x477835" unitRef="iso4217_USD" decimals="-3">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <acur:SharesWithheldForTaxValue contextRef="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x477835" unitRef="iso4217_USD" decimals="-3">886000</acur:SharesWithheldForTaxValue>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x477835">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:OptionNonCashExercise1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441864">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_455296x441133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698_455296x477835">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:OptionNonCashExercise1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698_455296x441133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x477835">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:OptionNonCashExercise1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581_455296x441133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920_455296x477835">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:OptionNonCashExercise1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920_455296x441133">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_455296x450439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x453698_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x440920_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x450439">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_455296x441864">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920_455296x477829">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">acur:WarrantNonCashExerciseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_365_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <startDate>2009-01-01</startDate>
      <endDate>2009-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20111231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20091231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20081231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20081231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <instant>2008-12-31</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE7738----1110-K0013_STD_0_20120229_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000786947</identifier>
    </entity>
    <period>
      <instant>2012-02-29</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
</xbrl>